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Targeted biologic agents have an established role in treating metastatic colorectal cancer (CRC), and the integration of targeted
therapies into the treatment of CRC has resulted in signiﬁcant improvements in outcomes. Rapidly growing insight into the
molecular biology of CRC, as well as recent developments in gene sequencing and molecular diagnostics, has led to high
expectations for the identiﬁcation of molecular markers to be used in personalized treatment regimens. The mechanisms of
action and toxicities of targeted therapies diﬀer from those of traditional cytotoxic chemotherapy. Targeted therapy has raised
new insight about the possibility of tailoring treatment to an individual’s disease, the assessment of drug eﬀectiveness and toxicity,
and the economics of cancer care. This paper covers the last decade of clinical trials that have explored the toxicity and eﬃcacy of
targeted agents in locally advanced and metastatic CRC and how their role may beneﬁt patients with rectal cancer. Future eﬀorts
should include prospective studies of these agents in biomarker-deﬁned subpopulations, as well as studies of novel agents that
target angiogenesis, tumor-stromal interaction, and the cell signaling pathways implicated in rectal cancer.
1.Introduction
Over the past 30 years, the management of rectal cancer
has undergone many signiﬁcant changes. Until the 1980s,
surgery was the mainstay of therapy for patients with rectal
cancer conﬁned to the bowel and regional lymph nodes [1].
However, local recurrence occurred in approximately 25% to
50%ofpatientswithT3orlymphnode-positiverectalcancer
[2]. These local failures, as well as distant metastases, were a
serious problem in locally advanced rectal cancer (LARC).
To reduce these high failure rates, multiple trials eval-
uated diﬀerent strategies of adjuvant radiation and 5-
ﬂuorouracil- (5-FU-) based chemotherapy [1, 3, 4]. Trial
results demonstrated postoperative adjuvant chemoradio-
therapy improved local control and survival compared with
surgery alone, leading to the routine integration of adjuvant
combined modality therapy into standard practice. At the
same time, total mesorectal excision (TME) was introduced
and further decreased local failure rates to less than 10% [5].
Subsequently, the landmark trial conducted by the German
Group established superior local control, reduced treatment-
related toxicity, and an improved sphincter preservation
rate with neoadjuvant chemoradiotherapy compared with
adjuvant 5-FU-based chemoradiation [6].
Today, although not proven to provide survival advan-
tages (except in the pivotal Swedish trial), preoperative
chemoradiotherapy with concurrent infusional 5-FU and
more recently the oral ﬂuoropyrimidine, capecitabine, fol-
lowed by TME has become the standard of care for patients
with T3 or lymph-node-positive rectal cancer, especially in
tumors of the mid- and lower rectum [7, 8]. The use of
targeted agents in patients with advanced colorectal cancer
has led to further improvements in disease-free (DFS) and
overall survival (OS), and further investigation in various
settings is underway [9–12]. These “targeted” agents are
now being studied in the treatment of rectal cancer and are
discussed below.2 International Journal of Surgical Oncology
2.TargetedAgents
Targeted therapies block the growth of cancer cells by inter-
fering with speciﬁc targeted molecules needed for carcino-
genesis and tumor growth [13]. Targeted cancer therapies
may also be more eﬀective by being potentially less harmful
to normal cells. Two main categories of targeted therapy
exist: small molecules (-nib) and monoclonal antibodies
(-mab), both of which can be further subdivided as either
signal transduction pathway inhibitors (imatinib mesylate,
trastuzumab, cetuximab) or angiogenesis inhibitors (beva-
cizumab, sunitinib).
Increasing knowledge of tumor growth and dissemi-
nation pathways has turned more attention to the use of
targeted agents coupled with chemotherapy in the treatment
of metastatic colorectal cancer (mCRC). For these patients,
phase III trials have shown improved disease-free and
overall survival rates using epidermal growth factor receptor
(EGFR) and vascular endothelial growth factor (VEGF)
inhibitors when combined with conventional chemotherapy
[9–12]. In this paper, we have reviewed VEGF and EGFR
receptor inhibitors selectively and how their use may or
may not be beneﬁcial in the setting of rectal cancer as a
radiosensitizer or in the adjuvant setting of rectal cancer. The
majorityofnoveltrialsdiscussedareinphaseIIdevelopment
and are presented here due to their potential beneﬁt in rectal
cancer.
2.1. VEGF Receptor Inhibitors. Bevacizumab is a humanized
monoclonal antibody that targets the vascular endothelial
growth factor (VEGF), particularly VEGF-A, a ligand with
a key role in angiogenesis. Angiogenesis is required for
tumor growth and malignant progression, and VEGF is
a crucial regulator of this process. Indeed, high VEGF
expression has been linked to a statistically higher risk of
local recurrence and metastasis [18]. Thus, the inhibition
of VEGF is a logical target for the treatment of patients
with CRC. In addition, anti-VEGF antibodies enhance the
capacity of radiotherapy to reduce tumor vascular density
and interstitial ﬂuid pressure (IFP) in xenografts [19].
These ﬁndings taken together support what is known
as the vascular normalization hypothesis [20]. According to
this hypothesis, an excess of proangiogenic factors within
tumors leads to functionally and structurally abnormal
vasculature that promotes increased IFP, a known barrier to
drugdeliverytotumors,andimpaireddeliveryofoxygenand
macromolecules, a known barrier to the eﬀective radiation
therapy [20–22].
One theory is that by “normalizing” this abnormal
vasculature, transient antiangiogenic therapy reduces IFP
and thereby increases the concentration of oxygen and pen-
etration of cytotoxics, improving the overall eﬀectiveness of
combined modality therapy [20]. In the same study, a variety
of plasma and circulating cell biomarkers were measured.
Both VEGF and placenta-derived growth factor (PIGF) were
found to be signiﬁcantly elevated by bevacizumab alone and
by combination therapy. These molecules may prove to be
potential biomarkers for anti-VEGF therapy, as increases
of pretreatment soluble VEGF receptor-1 (s-VEGFR1) and
PIGF levels have also been associated with poor patho-
logic tumor downstaging after preoperative chemoradiation
[29, 30].
2.2. EGFR Receptor Inhibitors. T h ee p i d e r m a lg r o w t hf a c t o r
receptor (EGFR) is a cell surface 170,000 daltons tyro-
sine kinase transmembrane receptor of the ErbB family,
whose members play a critical role in oncogenesis [31].
In particular, EGFR has been shown to participate in the
progression of CRC, as it is essential for tumor growth and
division [32]. Some CRCs have been shown to overexpress
EGFR, and overexpression of EGFR is associated with poorer
prognosis [33, 34], and with resistance to radiation therapy.
EGFR has, therefore, become an attractive target for therapy,
and two diﬀerent classes of biologic agents have been
evaluated: the EGFR monoclonal antibodies (cetuximab
and panitumumab) and the small-molecule tyrosine kinase
inhibitors (geﬁtinib and erlotinib).
The eﬃcacy of both cetuximab and panitumumab has
been clearly demonstrated to depend upon the KRAS
mutation status. Multiple analyses have demonstrated that
responses to either cetuximab or panitumumab occur exclu-
sively within the 60–70% of patients without activating
mutations in codon 12 and 13 of KRAS [23, 24, 28, 35]. The
activating V600E BRAF mutation is present in an additional
10%ofpatients,anditmaybepredictiveofalackofresponse
to anti-EGFR therapy [36] in addition to a clear poor
prognostic factor. The anti-EGFR monoclonal antibodies
and their predictive biomarkers have taken CRC treatment
another step closer to personalized therapy. However, the
recentresultsofthelargeUKCOINstudyandaBelgianstudy
have not conﬁrmed a beneﬁt in terms of PFS or OS from the
addition of cetuximab to oxaliplatin-based chemotherapy
in wild-type KRAS patients versus 5-FU and oxaliplatin
alone[37,38].Therefore,morethoughtfullydesignedstudies
about potential negative predictive factors such as KRAS,
BRAF, NRAS, PIK3CA mutations, and EGFR gene copy
numbers would be beneﬁcial.
3.ClinicalUses of TargetedAgents
3.1. Metastatic CRC. Bevacizumab, cetuximab, and pani-
tumumab have been proven to be eﬀective in diﬀerent
combined chemotherapy treatment settings for metastatic
colorectal cancer and are brieﬂy described here (Tables 1 and
2)[ 9–12].
3.1.1. Bevacizumab. Bevacizumab, a monoclonal antibody
against the vascular endothelial growth factor ligand (VEGF-
A), has demonstrated eﬃcacy with signiﬁcant improvement
in progression-free survival (PFS) and OS in patients with
metastatic colorectal cancer [9, 16, 39]. Results from a
pivotal phase III trial of bevacizumab (5mg/kg) showed
a signiﬁcantly greater OS, PFS, and response rate (RR)
when used in combination with irinotecan, bolus 5-FU, and
leucovorin (IFL), in 813 patients with previously untreated
colorectal cancer [9]. The median OS was 20.3 months in
the patients treated with bevacizumab, compared to 15.6International Journal of Surgical Oncology 3
Table 1: Pivotal randomized clinical trials of bevacizumab in mCRC.
Author Phase Study design (regimen) N
+Bev/− Results Comment Reference
1st line
Hurwitz III IFL ± bevacizumab 402/411 20.3 versus 15.6 mo OS RR,PFS,OS beneﬁt [9]
Scappaticci II 5FU/LV ± bevacizumab 104/105 9.2 versus 5.5 mo PFS
No diﬀerence in OS,
IFL was included in
control group
[14]
Czito III IFL ± bevacizumab 249/251 17.9 versus 14.6 mo OS RR,PFS,OS beneﬁt [15]
Saltz III CAPOX or FOLFOX ±
bevacizumab 699/701 9.4 versus 8.0 mo PFS No diﬀerence in OS [16]
2nd line
Giantonio III FOLFOX ±
bevacizumab 286/291 12.9 versus 10.8 mo OS
RR,PFS,OS beneﬁt,
No beneﬁt in Bev
alone group
[17]
RR: Response rate, PFS: Progression-free survival, OS: Overall survival.
Table 2: Pivotal randomized clinical trials of cetuximab in mCRC.
Study Phase Study design(regimen) N
+Cet/− Results Comment Reference
1st line
CRYSTAL III FOLFIRI ± cetuximab 599/599 No diﬀerence in OS PFS,OS beneﬁt in KRAS-WT [23]
OPUS II FOLFOX ± cetuximab 169/168 46 versus 36% RR No diﬀerence in OS [24]
CAIRO-2 III CAPOX + beva ± cetuximab 377/378 9.4 versus 10.7mo
PFS [25]
COIN III CAPOX or FOLFOX ±
cetuximab 815/815 17 versus 17.9 mo OS No diﬀerence in PFS,OS in
KRAS-WT [26]
NORDIC VII III FLOX ± cetuximab 194/185 19.7 versus 20.4mo
OS
No diﬀerence in PFS,OS in
KRAS-WT [27]
2nd line
BOND II Irinotecan ± cetuximab 218/111 22.9 versus 10.8% PR [10]
CO.17 III Cetuximab versus supportive
care 287/285 6.1 versus 4.6 mo OS 9.5 versus 4.8 mo OS in
KRAS-WT [11, 28]
RR: Response rate, PFS: Progression-free survival, OS: Overall survival. KRAS-WT: KRAS wild type.
months with the placebo-containing regimen (P<. 001),
and response rates were 44.8% and 34.8%, respectively (P =
.004). Also of note was the phase III Bevacizumab plus
Irinotecan in Colorectal Cancer (BICC)-C trial, consisting of
two-arms: FOLFIRI(infusional FL) plus bevacizumab, versus
mIFL (Bolus FL) plus bevacizumab. The median OS with
the addition of bevacizumab was longer with FOLFIRI than
with mIFL (28.0 versus 19.2 months; P = .037) [40, 41].
These ﬁndings led to the U.S./European Union approval of
bevacizumab as a ﬁrst-line-therapy component for mCRC
with any 5-FU- based therapy.
The most commonly used bevacizumab-based ﬁrst-
line treatment in the USA continues to be FOLFOX plus
bevacizumab. It was presumed that the beneﬁt of adding
bevacizumab to FOLFOX would be similar to that demon-
strated with the IFL regimen, and that the addition of beva-
cizumab to FU-based combination chemotherapy would
result in a signiﬁcant and clinically meaningful improvement
in survival among patients with mCRC [39]. Except in
cases of major contraindications for bevacizumab, such as
severe vascular disease or prior arterial thrombotic events,
bevacizumab can be integrated with ﬁrst-line chemother-
apy in patients with metastatic CRC. In the event that
a bevacizumab-na¨ ıve patient fails ﬁrst-line chemotherapy,
bevacizumab may be considered as a second-line treat-
ment. In fact, the Bevacizumab Regimens: Investigation of
Treatment Eﬀects and Safety (BRITE) observational study
conﬁrmed that a notable OS beneﬁt was demonstrated in
thosepatientswhocontinuedbevacizumabtherapy(5mg/kg
every 2 weeks) in combination with chemotherapy, after
disease progression following a bevacizumab-based regimen
(median OS, 31.8 months) [42]. The ARIES study validated
the ﬁndings of BRiTE and reported a median OS of 24.7
months [43]. Furthermore, a recent randomized phase III4 International Journal of Surgical Oncology
European trial (TML) suggests continuation of bevacizumab
improves OS with ﬁnal results to be reported at a later
date [44].
3.1.2. Cetuximab. Cetuximab plus irinotecan is the standard
treatment in irinotecan-refractory patients based on pivotal
data from the Bowel Oncology with Cetuximab Antibody
(BOND) trial, which established this as an eﬀective regimen
regardless of prior treatment history [10]. This trial con-
ﬁrmedtheactivityofcetuximabwithresponseratesof22.9%
and 10.8% for combination therapy and monotherapy,
respectively. In addition,there was a signiﬁcantly longer time
to tumor progression in favor of the combination arm (4.1
versus 1.5 months).
In a subsequent retrospective analysis of patients with
KRAS wild-type tumors, there was an OS beneﬁt for patients
in favor of cetuximab (9.5 versus 4.8 months) [28]. Given
cetuximab’s demonstrated eﬃcacy in the chemotherapy
treatment-resistant setting, several studies were undertaken
to evaluate its eﬃcacy in the treatment-naive setting. The
randomized,phaseIIICRYSTALtrialevaluated1198patients
treated with FOLFIRI chemotherapy either with or with-
out cetuximab, and noted improvement in PFS for the
cetuximab-treated group [23]. However, it was also noted
that no OS beneﬁt was associated with the cetuximab-
treated arm, potentially due to the fact that there was a
diﬀerence in subsequent poststudy anti-EGFR therapy (23%
in the FOLFIRI arm received subsequent cetuximab therapy,
compared to 5.2% in the FOLFIRI + cetuximab arm) [49].
Retrospective tissue analysis on the CRYSTAL study revealed
that the beneﬁt from cetuximab was restricted to those
patients with KRAS wild-type tumors and that it improved
the PFS to 9.9 months compared to 8.4 months in the
control arm. Subsequent analysis of the 666 patients with
KRAS wild-type tumors who were enrolled has shown an
OS improvement from 20 months in the control arm to 23.5
months in the cetuximab arm [50].
The randomized Phase II OPUS trial demonstrated simi-
lar ﬁndings when cetuximab was used with oxaliplatin-based
chemotherapy; cetuximab, when combined with FOLFOX-
4 chemotherapy, led to an improvement in PFS, when
compared to those treated with FOLFOX-4 chemother-
apy alone [51]. Similarly, the beneﬁt derived from this
therapy was limited to those patients with KRAS wild-
type tumors (7.7 versus 7.2 months). However, these
results have not been replicated in the phase III MRC-
COIN study, where cetuximab was added to FOLFOX or
CapeOX (capecitabine/oxaliplatin) in the ﬁrst-line setting;
those treated with capecitabine-based therapy fared worse
[37]. Based on currently available data, it appears to
be advantageous when cetuximab is added to irinotecan-
based regimens while the advantage of combination with
oxaliplatin remains less certain [26, 52]. Cetuximab can lead
cancer cells to G1 or G2/M cell cycle arrest and upregulate
several genes involved in proliferation (PIK31, CGREF1, and
PLAGL1) with a reduction in Ki-67 [38]. But if only a small
proportion of cells arrest in G0/G1 or G2/M, slowing down
the cell cycle time may actually increase the amount of time
available for DNA repair prior to mitosis, and thus could
increase resistance to chemoradiation.
3.1.3. Panitumumab. Two phase III trials have deter-
mined the beneﬁt of panitumumab in combination with
chemotherapy relative to chemotherapy alone. The ﬁnal
reported results were selected for KRAS wild-type status as
a predictive marker for anti-EGFR therapy in both studies.
The Panitumumab Randomized Trial in Combination with
Chemotherapy for Metastatic Colorectal Cancer to Deter-
mine Eﬃcacy (PRIME) was a phase III randomized trial
of FOLFOX with or without panitumumab in previously
untreated patients [53]. The PFS time was longer in the
panitumumab arm (9.6 versus 8.0 months, P = .02). The
role of panitumumab was also investigated in combination
with FOLFIRI for second-line treatment [54]. The primary
endpoint of a PFS diﬀerence (5.9 versus 3.9 months; P =
.004) was fulﬁlled with the addition of panitumumab but the
OS endpoint was not met.
3.2. Adjuvant Setting
3.2.1. Bevacizumab. In the adjuvant treatment of colon can-
cer, two phase III trials did not demonstrate any beneﬁt from
the addition of bevacizumab to standard oxaliplatin-based
chemotherapy in stage II/III colon cancer [55, 56]. From the
results of the NSABP C-08 trial, in which bevacizumab in
combination with FOLFOX6 did not improve DFS in the
adjuvant setting in patients with stage II/III colon cancer,
it seems that bevacizumab’s eﬃcacy may be maximal in a
setting of more advanced disease [1]. The AVANT (Avastin
adjuvant) study compared FOLFOX4 versus FOLFOX4 with
bevacizumab versus XELOX with bevacizumab in 3,451
patients with stage II or III colon cancer. The study did not
meet its primary objectives, and survival in the bevacizumab
arms was inferior to the chemotherapy-alone arm [57].
3.2.2. Cetuximab. Two adjuvant trials have evaluated the
potentialbeneﬁtofcetuximabincombinationwithFOLFOX
in a KRAS wild-type population: NO147 and PETACC8.
There was no improvement in DFS or OS with the addition
of cetuximab to FOLFOX. The NO147 trial compared 12
cycles of the modiﬁed FOLFOX6 to the same regimen
with cetuximab [58, 59]. The 3-year DFS was even better
with FOLFOX alone: 75.8% versus 72.3% for FOLFOX plus
cetuximab. There was also a trend for 3-year OS inferiority:
87.8% with FOLFOX alone versus 83.9% for FOLFOX plus
cetuximab. The subset of 717 patients with KRAS-mutated
tumors did poorly with cetuximab. These observations
raise questions about the manner of interaction between
targeted therapies and chemotherapies and the mechanisms
ofinducingchemoresistanceinsomepatients.ThePETACC8
trial aims to increase the DFS in wild-type KRAS tumor
patients. The trial has completed enrollment with ﬁnal
results to be presented at a later date.
Thus far, we have provided a general overview of the
currentlyFDAapprovedrolefortargetedagentsinmetastatic
colorectal cancer as well as the investigational status of
targeted agents in locally advanced colon cancer. Overall,International Journal of Surgical Oncology 5
of the targeted agents discussed, many of them have been
analyzed to a much smaller extent in rectal cancer versus that
of colon cancer in phase I/II clinical trials.
4.LocallyAdvancedRectalCancer
Overall, challenges remain in improving the treatment of
locally advanced rectal cancer. Recent data from 3 phase III
trials including NSABP R-04, STAR, and ACCORD 12 [60–
62] have failed to provide a deﬁnitive role for oxaliplatin as
a radiation sensitizer. Targeted agents in combination with
ﬂuorouracil-based treatment continue to remain an area of
investigation.
4.1. Neoadjuvant Chemoradiation. Randomised phase III
trials of neoadjuvant preoperative chemoradiation (CRT)
in resectable rectal cancer show that the addition of 5-FU
to preoperative radiation increases the pathologic complete
remission (pCR) rate over radiotherapy alone and improves
loco-regionalcontrolbuthasnotextendedDFSorOS[6,63–
65] .S e v e r a ls m a l lp h a s eI / I Is t u d i e sh a v es i n c eb e e nc r e a t e d
in the hopes of improving the pCR rate further by using
combined chemotherapy with cytotoxic chemotherapy or
targeted agents. It should be noted that pCR remains a
common endpoint for many of current and prior trials in
development. To date, none of the targeted agents have
proceeded to phase III development as a radiation sensitizer
with only one proceeding to the adjuvant setting of rectal
cancer.
4.1.1.Bevacizumab. Giventhedatasupportingtheeﬃcacyof
bevacizumab therapy in metastatic colorectal cancer [17], it
was postulated that combining bevacizumab with chemora-
diation may increase antitumour eﬃcacy by maximizing
inhibition of the VEGF pathway. In an early trial of beva-
cizumab plus infusional 5-FU and radiation in stage II/III
rectal cancer, bevacizumab administered as a single agent
14 days prior to chemoradiation induced normalization of
tumour vasculature and reduced interstitial ﬂuid pressure
[66]. Willett et al. ﬁrst reported on a phase I trial of
bevacizumab in combination with preoperative 5-FU and
radiation. Surgery was scheduled 7–9 weeks later. A pCR
rate of 16% was reported, and an additional 72% of patients
had only microscopic foci remaining after treatment in their
phase I/II study of patients with T3/T4 tumors [29]. Crane
et al. reported results of a single institution phase II trial of
neoadjuvant bevacizumab, capecitabine, and radiation in 25
patients with locally advanced rectal cancer [47]. The pCR
rate was 32%, with an additional 24% of patients having
near-complete responses (less than 10% viable tumor cells).
Toxicity was generally mild, although wound dehiscence was
seen in 12% of patients (Table 3).
It should be noted that bevacizumab was to be evaluated
in the adjuvant setting following deﬁnitive chemoradiation
therapyinlocallyadvancedrectalcarcinomapatients(ECOG
5204). This was a randomized phase III trial of adjuvant
FOLFOX +/− bevacizumab. However, this study closed
prematurely due to slow patient accrual but would have
closed eventually given the results of NSABP C-08.
4.1.2. Cetuximab. EGFR is also a rational target in combina-
tion with radiotherapy. Data from a variety of experimental
models and human tumors suggest that EGFR signaling
promotes resistance to radiotherapy by activating cell sur-
vival signals through Akt [73, 74]. Moreover, retrospective
analyses demonstrated shorter DFS and smaller pCR rates
in patients with rectal cancers expressing EGFR who were
being treated with neoadjuvant radiotherapy [75, 76]. These
datasuggestthepossibilityofenhancingradiosensitivitywith
EGFR-directed therapy.
A landmark randomised phase III study in patients
with locally advanced head and neck cancer showed that
cetuximab in combination with radical radiotherapy signiﬁ-
cantly improved overall survival [77] compared to radiation
alone [78]. Many mechanisms for this advantage have been
proposed, including inhibition of repopulation during the
latter phase of radiotherapy [79, 80]. Chung et al. treated
20 patients with ultrasound-staged (u)T3 to 4, clinical T4,
or locally recurrent rectal cancer with weekly cetuximab and
5-FU during 5.5 weeks of pelvic radiotherapy, followed by
an additional 4 weeks of cetuximab [81]. Patients underwent
surgical resection 1 to 3 weeks after the completion of ther-
apy. Cetuximab in conjunction with 5-FU and radiotherapy
was feasible without synergistic or unexpected toxicities;
the pCR rate was 12%. According to the meta-analysis of
13 reports, the addition of cetuximab to ﬂuoropyrimidine-
based CRT schedules suggest an overall pooled pCR of
9.1%, compared with an overall pCR rate of 13.5% seen
with ﬂuoropyrimidine-based chemoradiation schedules in
ar e c e n tr e v i e w( T a b l e4)[ 82] .T h ep C Rr a t e sh a v eb e e n
disappointingly low, perhaps because anti-EGFR therapy
is most eﬀective in inhibiting the accelerated repopulation
observed after the higher doses of radiotherapy used in
patients with head and neck cancer [47].
Alternatively,cetuximab-inducedinhibitionofmitogenic
signaling through the extracellular signal-regulated kinase
(Erk) pathway may mitigate the radiosensitizing eﬀect of S
phase-speciﬁc chemotherapy. Cetuximab can lead to G1 or
G2/M cell cycle arrest, and if only a small proportion of cells
within the tumour are aﬀected, this decrease in proliferation
could impact the chance of achieving a pCR [38]. This
process might also aﬀect oxaliplatin, which is mainly active
in S phase but would be less likely to aﬀect irinotecan. Thus,
preclinical data suggests that the sequencing of chemother-
apymayhavesomesigniﬁcancebutgiventheprolongedhalf-
life of cetuximab, it may not necessarily apply to the clinical
setting [83]. In light of this hypothesis, a phase I/II study
(XERXES) created to compare a schedule of capecitabine-
based chemoradiation with a cetuximab sandwich approach
amended their protocol [84].
4.1.3. Panitumumab. Panitumumab was administered
before the start of CRT, and every 2 weeks in combination
with 5FU-oxaliplatin with concurrent RT(StarPan/STAR-02
study) [85]. Rate of pCR was 21.1% and pathological
downstaging occurred in 57.9% of the patients. Higher pCR
rate in comparison with the results of previous neoadjuvant
rectal cancer trials with antiepidermal growth factorreceptor
monoclonal antibodies supports further studies necessary6 International Journal of Surgical Oncology
Table 3: Clinical trials of bevacizumab in preoperative treatment of rectal cancer.
Author Phase Study design(regimen) N RT dose
(Gy) pCR rate Major wound Cx Reference
Machiels I Cape + oxali + bevacizumab 11 50.4 2/11(18%) NS [45]
Willett II 5FU + bevacizumab 32 50.4 5/32(16%) 1/32(3%) [29]
Rodel II 5FU + bevacizumab 35 50.4 10/35(29%) 3/20(15%) [46]
Crane II Capecitabine + bevacizumab 25 50.4 8/25(32%) 3/25(12%) [47]
Mourad II Xelox + beva then cape + beva + RT 47 50.4 16/47(36%) 11/47(24%) [48]
RT: Radiotherapy, pCR: Pathological complete response.
Table 4: Clinical trials of cetuximab in preoperative treatment of rectal cancer.
Author Phase Study design(regimen) N RT dose
(Gy) pCR rate Diarrhea (≥ G
3) Reference
Kuo I 5FU+ cetuximab 20 50.4 2/17(12%) 2/20(10%) [67]
Bertolini I Caplri + cetuximab 20 50.4 5/20(25%) 2/10(20%) [68]
Velenik I/II Capecitabine + cetuximab 40 45 2/40(5%) 6/40(15%) [69]
Horisberger I/II CAPOX + cetuximab 48 50.4 4/48(8%) 9/48(19%) [70]
Chang II Cetuximab then 5FU + cetux 40 50.4 3/40(7.5%) 3/40(7.5%) [71]
Rodel II Capecitabine + cetuximab 37 45 3/37(8.1%) 4/37(11%) [72]
Oncofacts.com II Caplri + cetuximab 50 50.4 4/50(8%) 15/50(30%) [44]
RT:Radiotherapy, pCR: Pathological complete response.
to understand the possibility of optimal regimens and
sequences with CRT.
4.1.4. Tyrosine Kinase Inhibitors of the EGFR. Though it
would appear to be intuitive that a tyrosine kinase inhibitor
of the EGFR receptor would be of potential beneﬁt, early
data for their role in mCRC has not been deﬁned and was
determined to be more toxic [67, 86]. However, the small
molecule tyrosine kinase inhibitors have radiosensitization
properties. A phase I trial of a combination of erlotinib
and bevacizumab with preoperative chemoradiotherapy of
capecitabine demonstrated an impressive pCR(44%) [87].
Similar preliminary results were also reported of a phase
I/II trial of bevacizumab and erlotinib in combination with
5-FU and pelvic radiotherapy for patients with clinical T3/4
rectal cancer [88]. No dose-limiting toxicities were reported
and erlotinib at a dose of 100mg was chosen as the MTD.
At the time of last followup, the reported pCR was 47% and
there were no local recurrences reported in patients who
completed study therapy. Thus, based on these phase I/II
trials, bevacizumab and erlotinib in combination with 5-FU
or capecitabine and radiotherapy appear to be well tolerated
and a potentially active preoperative regimen for patients
with LARC.
4.2. Induction Chemotherapy. While modern rectal cancer
trials with trimodality therapy have reported locoregional
recurrence rates of less than 10%, especially with TME,
systemic treatment can be delayed for up to 3-4 months
followingtheoriginaldiagnosis[89,90].Theproblem,there-
fore, remains the persistent high rate of distant metastasis
(30–35%) in this disease [91, 92]. Reasons for this higher
rate of distant failure may be complex. One such reason,
the biological response of tumors to radiation, may provide
explanationinthattumorsthatarenotcompletelyeradicated
undergo accelerated repopulation [93].Thus, integrating
more eﬀective systemic therapy into combined modality
programs is the challenge and induction chemotherapy has
the advantage of earlier administration of systemic therapy
and may improve distant control. Theoretically, tumour
shrinkage with chemotherapy potentially allows improved
tumour vascularity and improved oxygenation and higher
intratumoural levels of cytotoxic drugs. These factors in turn
may enhance tumour sensitivity to chemotherapy or radia-
tion [94]. Therefore, newer generation chemotherapeutics as
well as targeted agents (cetuximab, bevacizumab) have been
incorporated into phase I-II studies [95, 96].
Interestingly, early results from the phase III ACCORD
12/0405-Prodige 2 and STAR trial did not conﬁrm a
signiﬁcant improvement of the primary endpoint, pCR
rate, with the addition of oxaliplatin to preoperative 5-FU-
based CRT [91, 92]. However, induction-capecitabine-based
CT prior to CRT reported eventual pCR rates as high as
24% [97, 98]. In a randomized comparison of induction
versus adjuvant capecitabine plus oxaliplatin, no diﬀerence
inclinicaloutcomeswasobservedbetweenthetwotreatment
regimens, although the induction regimen resultedin a more
f a v o r a b l es a f e t yp r o ﬁ l e[ 99]. To date, the 3-year DFS and OS
remain unchanged versus the control arm [100].
In the AVACROSS study, treatment consisted of beva-
cizumab and XELOX, followed by concomitant radiotherapy
plus bevacizumab and capecitabine. pCR was achieved in
36%ofthepatientsbuttherateofpostsurgicalcomplications
and cardiac toxicity was not negligible. Most were associatedInternational Journal of Surgical Oncology 7
with wound-healing complications with 24% of patients
requiring further surgery; note that patients with a previous
history ofstableangina,arrhythmia,andcoronarysyndrome
should be excluded [101]. Emerging evidence from several
phase I-II trials indicate that induction chemotherapy for
rectal cancer patients is feasible and does not compromise
CRT or surgery, but only an adequately powered phase III
trial will answer the question deﬁnitively.
An interesting multinational randomised phase II study,
EXPERT-C trial (NCT00383695), compares neoadjuvant
therapy comprising oxaliplatin, capecitabine, and CRT with
or without cetuximab in 164 patients. It was designed on
the basis of earlier single-arm phase II study (EXPERT),
in which patients received 12 weeks of neoadjuvant
capecitabine and oxaliplatin followed by chemoradiotherapy
with capecitabine, TME, and 12 weeks of postoperative
adjuvant capecitabine [97]. Radiological response rate after
neoadjuvant chemotherapy and chemoradiotherapy was
89% (93/105) with a reported pCR of 20%. Three-year
PFS and OS were 68% and 83%, respectively. Early results
of the EXPERT-C trial indicate that improved 3-yr OS in
patients receiving the investigational arm with CRT was 96%
compared with 81% among those who received neoadjuvant
chemotherapy and chemoradiation alone [102]. In the
KRAS wild-type group, there was no statistically signiﬁcant
diﬀerence in PFS (81 versus 80%) and pCR (7 versus 11%)
[7]. Though a phase II trial, the results of EXPERT-C have
potentially renewed interest of investigators for oxaliplatin
and cetuximab in the treatment of rectal cancer; results will
need to be validated in a phase III trial.
4.3. Novel Targeted Agents in Phase III Clinical Trials. Several
novel agents are being studied in phase III trials for the
treatment of metastatic colorectal cancer: aﬂibercept, ramu-
cirumab, regorafenib, perifosine, and brivanib. Of these,
aﬂibercept and ramucirumab are speciﬁc VEGF-directed
therapies, whereas the remaining three are associated with
approaches to intracellular signal blockade.
Aﬂibercept is a fully human, recombinant fusion pro-
tein that functions as a soluble decoy receptor for VEGF,
with aﬃnity for VEGF-A, VEGF-B, and placental growth
factor [103]. The VELOUR trial is a randomized, placebo-
controlled study investigating the combination of FOLFIRI
plus aﬂibercept versus FOLFIRI in the second-line treat-
ment of mCRC [104]. Ramucirumab is another human
monoclonal antibody directed against VEGFR-2, which is
considered to be the primary VEGFR mediating the process
of tumor angiogenesis [105, 106]. It is currently in phase
III development in 2nd-line metastatic colorectal cancer in
combination with FOLFIRI [107].
Regorafenib is a diphenylurea oral multikinase inhibitor
that targets a variety of kinases implicated in angiogenic
and tumor growth-promoting pathways and has been
investigated as a single-agent activity in the phase III
CORRECT trial in refractory mCRC [108]. The ﬁnal results
of the CORRECT trial noted improved OS versus best
supportive care alone (6.5 versus 5.0mo, P<. 0052) [109].
Perifosine is an oral alkylphospholipid that inhibits several
key signal transduction pathways, including Akt, JNK, and
NF-κB. Inhibition of NF-κB signaling by perifosine has
been reported to restore 5-FU chemosensitivity [110, 111].
The Xeloda plus Perifosine Evaluation in Colorectal Cancer
Treatment (X-PECT) trial with a target enrollment of 430
patients has recently completed accrual [112]. Perifosine
has been evaluated preclinically in prostate and glioma as a
radiation sensitizer [113, 114]. Brivanib is an oral receptor
tyrosine kinase inhibitor that speciﬁcally inhibits the VEGF
and ﬁbroblast growth factor (FGF) signaling pathways [115,
116]. Recent phase III data failed to show a beneﬁt in
OS when brivanib was added to cetuximab in KRAS-WT
metastatic CRC patients [117]. Brivanib continues to be
investigatedincombinationinasingleinstitutionaltrialwith
irinotecan in an enriched patient population with a focus on
plasma ﬁbroblast growth factor (pFGF) [118].
Currently, perifosine appears to be the only targeted
agent in phase III development with some potential as
a radiation sensitizer based on preclinical studies. Hence,
though greater than 50 novel agents are being investigated
in phase II trials, only a small percentage of these agents
will proceed to phase III clinical trial development with a
minority eventually investigated for their radiosensitization
properties. Therefore, it is important to identify predictive
biomarkers for chemotherapy and radiation sensitivity, a
task that should involve close cooperation and discus-




5.1. Bevacizumab. Bevacizumab is accompanied by a man-
ageable safety proﬁle. Early-phase II and pivotal-phase
III studies in CRC utilizing bevacizumab have identiﬁed
hypertension (11%–32%), bleeding (mainly epistaxis; 30%–
53%), proteinuria (10%–38%), arterial thromboembolism
(ATE) (1%–10%), gastrointestinal perforation (0.3%–2%),
and wound healing (1.3%–3.7%) as bevacizumab-associated
adverse events.
Hypertension is the most commonly reported associated
toxicity of patients treated with bevacizumab [9, 42]. The
mechanism of bevacizumab-related HTN is unclear and
has been attributed to possible alterations in the nitric
oxide signaling pathway and the endothelial dysfunction
of the renin-angiotensin system [48, 119]. There are no
clear guidelines for the management of hypertension in
patients receiving bevacizumab, but patients who develop
more than grade 2 HTN during bevacizumab therapy should
be managed using standard antihypertensive therapy.
Incidence of grade 3/4 proteinuria in recent phase
III trials with bevacizumab in metastatic CRC have been
reported in less than 2% of patients [9, 42]. The mechanism
of proteinuria is not fully understood but may be related
to the eﬀects of VEGF on the renal glomerular capillaries.
It is advisable that patients with proteinuria of more than
2+ on a dipstick should have a 24-hour urine check for
quantiﬁcation of protein. If patients develop proteinuria of
more than 2g/24 hours, bevacizumab administration should8 International Journal of Surgical Oncology
be interrupted until proteinuria improves. Patients should
be evaluated for ACE inhibitors or angiotensin-receptor
blockers as initial treatment in the case of development of
proteinuria with hypertension.
Bleeding from mucocutaneous membranes is common
with bevacizumab and occurs in 20% to 40% of patients
[120], the most signiﬁcant type being gastrointestinal bleed-
ing (6%) and the most common being self-limited epistaxis
(46%). Note that the BRiTE study did not exclude patients
on antiplatelet therapy or full-dose anticoagulation [121],
so it is relatively safe in terms of risk of serious bleeding
complications.
Thrombosis is a more potentially serious adverse event.
In the pivotal phase III trial in patients with metastatic CRC
evaluating the IFL regimen with and without bevacizumab,
the incidence of all venous and ATE was 19.4% versus 16.2%
in the nonbevacizumab arm [9]. It has been speculated
that the blockade of the VEGF receptors leads to apoptosis
of endothelial cells in the vasculature, thus exposing the
subendothelial collagen and initiating a coagulation cascade
resulting in an increased risk for thrombus formation [122].
Thus, the Food and Drug Administration (FDA) described
that the rate of ATE is increased in patients with prior
events of ATE or patients aged more than 65 years during
bevacizumab therapy.
Other less common but serious reported toxicities
may include gastrointestinal perforation (2%) and wound-
healing complications. Patients who underwent surgery
within 14 days of receiving bevacizumab are at a higher risk
of developing wound healing complications [14]. Based on
availabledata,bevacizumabshouldnotbeinitiatedwithin30
days after surgery. Elective surgeries should be planned 6 to 8
weeks after last dose of bevacizumab, though chemotherapy
alone can be continued until 2 to 3 weeks before surgery.
Furthermore, it has been suggested that extended use of
bevacizumab can increase the long-term risk of wound
healing complications for up to 6 months after its cessation
[55, 123].
The incidence of GI perforations may be slightly higher
in patients with an intact primary tumor, prior adjuvant
radiation therapy in rectal cancer, long-term nonsteroidal
anti-inﬂammatory drug (NSAID) therapy (≥1 month of
use), peptic ulcer disease, diverticulosis, and previous gas-
trointestinal surgery [9, 100, 124]. An extensive meta-
analysis reported an incidence of GI perforation under
bevacizumab treatment of <1%, resulting in a mortality
of 22% [125]. Reversible posterior leukoencephalopathy
syndrome (RPLS) has been reported in clinical studies (with
an incidence of < 0.1%) and in postmarketing experience
[126]. RPLS is a neurological disorder, which can present
with headache, seizure, lethargy, confusion, blindness, and
othervisualandneurologic disturbances. Discontinuation of
bevacizumab and aggressive management of hypertension is
indicated in patients developing RPLS.
5.2. Cetuximab. The most frequently observed toxicity with
theuseofcetuximabisthedevelopmentofarash;allpatients
experience some degree of xerodermatitis. The majority will
develop a nonscarring, noninfectious, acneiform rash most
prominent on the malar aspect of the face, chest, and back;
it is exacerbated by sunlight. But the severity of the rash
has been correlated with improved response to cetuximab
therapy [127]. In view of this ﬁnding, a randomized, Phase
I-II study (the “EVEREST” trial) was developed, with the
experimental arm consisting of dose escalation of cetuximab
to rash development in those treated patients who failed
to develop a grade 2 rash following initial exposure to
cetuximab. While a higher radiographic response rate in the
experimental arm of this trial (the cetuximab dose escalation
to rash) was observed, this did not lead to an improvement
i nP F So rO Sa d v a n t a g e[ 128].
Cetuximab has also been frequently associated with
renal magnesium wasting leading to hypomagnesemia, with
this occasionally becoming symptomatic [129, 130]. When
symptomatic, repletion with enteral or parenteral magne-
sium is indicated; it is not clear that magnesium replacement
is beneﬁcial in an asymptomatic patient [131]. Paronychial
inﬂammation and ﬁssuring of the distal ﬁngertips are a class
eﬀect of these agents. If left unaddressed, severe paronychial
infections may develop. Instances of elevated cases of allergic
hypersensitivity reactions have been reported regardless of
the premedications provided [132]. The development of
IgE antibodies was noted and varied depending on the
geographic location with greater instances in the in the
Southern USA.
5.3. Panitumumab. In contrast to cetuximab, which is a
chimeric monoclonal antibody that may produce severe
hypersensitivity reactions in some patients, panitumumab is
afullyhumanmonoclonalantibodyandislesslikelytoresult
in allergic hypersensitivity reaction.
6. Pharmacoeconomic Considerations
Targeted therapy also introduces new economic considera-
tions.Targetedtherapyisoftenusedinadditiontotraditional
chemotherapy. If targeted therapy includes monoclonal anti-
bodies, costs can escalate exponentially. Pharmacoeconomic
studieslookingathealthcaresystemshavedemonstratedthat
the cost per life-year gained with biologics is relatively high,
compared with other interventions [133–136]. For example,
multidrug colorectal cancer treatment regimens containing
bevacizumab or cetuximab cost up to $30,790 for eight-
weeks of treatment, compared with $63 for an eight week
regimen of 5-FL, the standard treatment until the mid-1990s
[137, 138]. The Cost of Care Task Force of The American
Society of Clinical Oncology recently released a guidance
statement emphasizing the importance of physician-patient
discussion regarding the cost of care and the creation of
decision-making tools to allow patients to make informed
and educated decisions about their treatment [139].
7. Conclusions
Advances in rectal cancer therapy remain stagnant despite
new existing cytotoxic and targeted agents in the treatment
ofmetastaticcolorectalcancer.Traditionally,agentsthathave
been incorporated into rectal cancer trials are those that haveInternational Journal of Surgical Oncology 9
demonstrated promise in advanced and locally advanced
colorectal cancer. However, to date, the role of cytotoxic
agents as radiation sensitizers (i.e., oxaliplatin) have not
demonstrated improved eﬃcacy versus the standard of care,
ﬂuorouracil. Similarly, targeted agents have a deﬁnitive role
in the treatment of metastatic colorectal cancer. Yet, its role
in the treatment of rectal cancer as a radiation sensitizer has
yet to be determined. In short, therapeutic developments in
rectal cancer may lag behind because rectal carcinoma is not
a commonly pursued area of pharmaceutical development.
Furthermore, whether pCR is the optimal endpoint remains
controversial versus the more traditional outcome of DFS
or OS. Retrospective analyses have suggested that pCR is a
potential surrogate for DFS or OS [71, 72]. These ﬁndings
must be validated prospectively in a phase III trial.
Targeted agents continue to be evaluated in the phase
I/II setting with promising potential but have yet to be
proven to be superior to the standard of care, ﬂuorouracil-
based radiotherapy. Currently, the use of targeted agents is
best suited in the setting of a clinical trial. Future devel-
opments in rectal cancer should focus on the identiﬁcation
of molecular factors that have prognostic and predictive
signiﬁcancetoimprovetreatmentoutcomes.Researcheﬀorts
focusing on additional biomarkers will reﬁne our ability
to use these agents speciﬁcally in patient populations that
derive a meaningful beneﬁt. With concerns about health
care costs, it is also critical to create a pharmacoeconomic
framework guiding the clinical use of these agents. The
introduction of new therapeutic agents and the discovery
and validation of prognostic and predictive markers along
with new screening tools will enable oncologists to tailor
patient-speciﬁc chemotherapy by maximizing drug eﬃcacy
and minimizing adverse and possibly severe side eﬀects.
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